Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
This study found JAK inhibitors were associated with increased reporting of infections, embolism/thrombosis, neoplasms, and gastrointestinal perforations. While some of these were already known, it raises further concerns about malignancies and gastrointestinal issues, though major cardiovascular events were not significantly associated.